• 1
    Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 70210.
  • 2
    Braitstein P, Yip B, Heath KV et al. Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995–2000. AIDS 2003; 17: 20715.
  • 3
    Dube MP, Sprecher D, Henry WK et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 121624.
  • 4
    Currier JS. Cardiovascular risk associated with HIV therapy. J Acquir Immune Defic Syndr 2002; 31(Suppl. 1): S1623.
  • 5
    Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005; 21: 171725.
  • 6
    Aboud M, Elgalib A, Kulasegaram R et al. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007; 61: 46372.
  • 7
    Wierzbicki AS, Purdon SD, Hardman TC et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin 2008; 24: 60924.
  • 8
    Currier JS, Lundgren JD, Carr A et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118: e2935.
  • 9
    Vascular Programme. Putting Prevention First – Vascular Checks: Risk Assessment and Management. London, UK: Department of Health, 2008. Report No.: 287093.
  • 10
    Anderson KM, Odell PM, Wilson PW et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121(1 Pt 2): 2938.
  • 11
    Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336: 147582.
  • 12
    Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 9871003.
  • 13
    Wierzbicki AS, Reynolds TM. Vascular risk screening: possible or too much, too soon? Int J Clin Pract 2009; 63: 98996.
  • 14
    Bergersen BM, Sandvik L, Bruun JN et al. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 62530.
  • 15
    Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 117993.
  • 16
    Law MG, Friis-Moller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 21830.
  • 17
    British Cardiac Society, British Hypertension Society, Diabetes UK et al. JBS 2: the Joint British Societies’ guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl. 5): v152.
  • 18
    National Institute for Health and Clinical Excellence. Lipid Modification. London, UK: National Institute for Health and Clinical Excellence, 2008. Report No.: CG67.
  • 19
    EMIS National User Group. University of Nottingham. QResearch Database. QResearch Group 2009. (accessed July 2009).
  • 20
    Neil HA, Perera R, Armitage JM et al. Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract 2008; 62: 132231.
  • 21
    Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 22
    De Socio GV, Martinelli L, Morosi S et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? Scand J Infect Dis 2007; 39: 80512.
  • 23
    De Socio GV, Parruti G, Quirino T et al. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 2008; 57: 3340.
  • 24
    Knobel H, Jerico C, Montero M et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007; 21: 4527.
  • 25
    Law M, Friis-Moller N, Weber R et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003; 4: 110.
  • 26
    Brindle P, May M, Gill P et al. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart 2006; 92: 1595602.
  • 27
    Steyn K, Levitt NS, Hoffman M et al. The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre study. Ethn Dis 2004; 14: 23342.
  • 28
    Cappuccio FP, Oakeshott P, Strazzullo P et al. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 2002; 325: 1271.
  • 29
    Triant VA, Lee H, Hadigan C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 250612.
  • 30
    Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation in patients without diabetes. J Cardiovasc Risk 2002; 9: 18390.
  • 31
    Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 16038.
  • 32
    de Saint ML, Vandhuick O, Guillo P et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 2006; 185: 3617.
  • 33
    Currier JS, Lundgren JD. Guidelines for managing cardiovascular risk: an evolving area. Curr Opin HIV AIDS 2008; 3: 2056.
  • 34
    Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 181122.
  • 35
    Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006; 8: 191203.
  • 36
    Colafigli M, Di GS, Bracciale L et al. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med 2008; 9: 1729.
  • 37
    Bentue-Ferrer D, Arvieux C, Tribut O et al. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 2009; 5: 145568.
  • 38
    Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46: 12533.